AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. AstraZeneca PLC is placed fourth on our list among the best cancer stocks.

TheFly reported on January 6 that Barclays analyst James Gordon increased the price target on AZN to 16,500 GBp from 14,000 GBp. The firm maintained an Overweight rating on the shares.

On the same day, AstraZeneca announced statistically significant results from its Phase III TULIP‑SC trial of Saphnelo (anifrolumab) in systemic lupus erythematosus (SLE). Subcutaneous self-administration of Saphnelo led to a clinically significant reduction in disease activity at Week 52, with 56.2% of patients showing improvement as opposed to 37.1% in the placebo group. These results support saphnelo’s potential as an SLE therapy.

AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial

AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company advancing cancer care through a robust late-stage oncology pipeline, innovative targeted therapies, and immuno-oncology treatments, aiming to improve patient outcomes across multiple tumor types worldwide.

While we acknowledge the risk and potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.